Foundation Medicine, Johnson & Johnson collaborate in oncology research
Foundation Medicine has reported a collaboration with Johnson & Johnson Pharmaceutical Research and Development. The collaboration is focused on using Foundation Medicine's comprehensive clinical cancer genomic test to identify potential biomarkers to support J&JPRD oncology clinical development programs. Financial details of the agreement were not disclosed.
"We are very pleased to work with J&JPRD and for our test to be used in the ongoing clinical development of new targeted cancer therapies," said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. "Cancer care is being improved by new therapies that target the molecular drivers of individual tumors. Our test may help identify patients that are more likely to respond to targeted therapies, which could accelerate clinical development and give physicians additional ways to effectively treat patients. This collaboration is further validation of Foundation Medicine's approach and the value our comprehensive cancer genomic test can bring to pharmaceutical clinical trials."